Stocks
Regeneron Pharmaceuticals, Inc.REGN
NASDAQHealthcareBiotechnology$745.77-0.11%
A leading biotechnology firm specializing in the discovery and commercialization of medicines for serious diseases, Regeneron is particularly known for its work in ophthalmology, oncology, and immunology. Investors closely monitor its pipeline of innovative therapies and its strong revenue growth driven by flagship products like Eylea and Dupixent.
Market Cap: $77.5B52W Range: $476.49 – $821.11
Congressional Interest in Regeneron Pharmaceuticals, Inc. (REGN)
13 members of Congress have disclosed 50 trades in Regeneron Pharmaceuticals, Inc. (REGN), a Healthcare company. The buy/sell breakdown shows 17 purchases versus 33 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
13
Buys
17
Sells
33
Who in Congress Is Trading REGN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-27 | Alan Armstrong | buy | $1K – $15K |
| 2026-02-12 | Julia Letlow | buy | $1K – $15K |